Search

Your search keyword '"Pachi, Ioanna"' showing total 39 results
Start Over Author "Pachi, Ioanna"
39 results on '"Pachi, Ioanna"'

1. Jumping to conclusions bias, psychosis and impulsivity in early stages of Parkinson’s disease

Author

Pachi, Ioanna, Papadopoulos, Vassilis, Xenaki, Lida Alkisti, Koros, Christos, Simitsi, Athina Maria, Bougea, Anastasia, Bozi, Maria, Papagiannakis, Nikos, Soldatos, Rigas Filippos, Kolovou, Dimitra, Pantes, George, Scarmeas, Nikolaos, Paraskevas, Georgios, Voumvourakis, Konstantinos, Potagas, Constantin, Papageorgiou, Sokratis G., Kollias, Konstantinos, Stefanis, Nikos, and Stefanis, Leonidas

Published
2023
Full Text
View/download PDF

2. Precision Dopaminergic Treatment in a Cohort of Parkinson’s disease Patients Carrying Autosomal Recessive Gene Variants: Clinical Cohort Data and a Mini Review

Author

Koros, Christos, primary, Simitsi, Athina-Maria, additional, Papagiannakis, Nikolaos, additional, BOUGEA, ANASTASIA, additional, Antonelou, Roubina, additional, Pachi, Ioanna, additional, Sfikas, Evangelos, additional, Stanitsa, Evangelia, additional, Angelopoulou, Efthalia, additional, Constantinides, Vasilios C., additional, Papageorgiou, Sokratis, additional, Potagas, Constantin, additional, Stamelou, Maria, additional, and Stefanis, Leonidas, additional

Published
2024
Full Text
View/download PDF

5. Collet–Sicard syndrome due to cervical artery dissection disclosed by high‐resolution magnetic resonance imaging.

Author

Theodorou, Aikaterini, Lachanis, Stefanos, Papagiannopoulou, Georgia, Maili, Maria, Pachi, Ioanna, Velonakis, Georgios, Bakola, Eleni, Vassilopoulou, Sofia, and Tsivgoulis, Georgios

Subjects
CAROTID artery dissections, INTERNAL carotid artery, HYPOGLOSSAL nerve, MAGNETIC resonance imaging, CRANIAL nerves, CRANIAL nerve diseases
Abstract

Background and purpose: Cervical artery dissection (CAD) represents a leading cause of unilateral lower cranial nerve IX–XII palsy, known as Collet–Sicard syndrome (CSS). High‐resolution magnetic resonance imaging (HR‐MRI) is widely used in the evaluation of patients with CAD, providing information regarding vessel wall abnormalities and intraluminal thrombus. Methods: We present a patient with palsy of multiple lower cranial nerves in the context of CSS, attributed to unilateral spontaneous internal carotid artery dissection. Results: We describe a 68‐year‐old man with unremarkable previous history, who presented with subacute, gradually worsening dysphagia and hoarse voice. Clinical examination revealed right‐sided palsy of cranial nerves IX–XII. Three‐dimensional fat‐saturated black‐blood T1‐weighted high‐resolution vessel wall imaging disclosed spontaneous dissection with intramural hematoma along the distal right internal carotid artery. Neck MRI showed inward displacement of right aryepiglottic fold, right pyriform sinus dilatation, and right true vocal cord in middle position, indicative of right vagus nerve palsy, atrophy of right trapezius and sternocleidomastoid muscles, due to right spinal accessory nerve palsy, and unilateral tongue atrophy with fatty infiltration, characteristic for right hypoglossal nerve palsy. Conclusions: This case highlights the utility of high‐resolution vessel wall imaging and especially fat‐saturated T1‐weighted black‐blood SPACE (sampling perfection with application‐optimized contrast using different flip‐angle evolutions) sequences in the accurate diagnosis of CAD, revealing the characteristic mural hematoma and intimal flap. HR‐MRI is also valuable in the recognition of indirect signs of lower cranial nerve compression. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Precision Dopaminergic Treatment in a Cohort of Parkinson's Disease Patients Carrying Autosomal Recessive Gene Variants: Clinical Cohort Data and a Mini Review.

Author

Koros, Christos, Simitsi, Athina-Maria, Papagiannakis, Nikolaos, Bougea, Anastasia, Antonelou, Roubina, Pachi, Ioanna, Sfikas, Evangelos, Stanitsa, Evangelia, Angelopoulou, Efthalia, Constantinides, Vasilios C., Papageorgiou, Sokratis G., Potagas, Constantin, Stamelou, Maria, and Stefanis, Leonidas

Subjects
RECESSIVE genes, PARKINSON'S disease, GENETIC variation, DOPAMINE agonists, DOPA
Abstract

Introduction: Parkinson's disease (PD) patients harboring recessive gene variants exhibit a distinct clinical phenotype with an early disease onset and relatively mild symptoms. Data concerning individualized therapy for autosomal recessive PD forms are still scarce. Methods: Demographic and treatment data of a cohort of PD carriers of recessive genes (nine homozygous or compound heterozygous PRKN carriers, four heterozygous PRKN carriers, and three biallelic PINK1 carriers) were evaluated. Results: The average levodopa equivalent daily dose (LEDD) was 806.8 ± 453.5 (range 152–1810) in PRKN carriers and 765 ± 96.6 (range 660–850) in PINK1 carriers. The majority responded to low/moderate doses of levodopa. The response to dopamine agonists (DAs) was often favorable both as initial and longitudinal therapy. In total, 8/13 PRKN and 1/3 PINK1 carriers were treated with amantadine successfully, and this also applied to patients who could not tolerate levodopa or DAs. Conclusions: In the era of personalized treatment, the therapeutic approach in recessive PD gene carriers might differ as compared to idiopathic PD. Lower LEDD doses were efficient even in patients with a very long disease duration, while a few patients were doing well without any levodopa treatment decades after disease initiation. DAs or amantadine could be used as a first and main line treatment regimen if well tolerated. Literature data on therapeutic strategies in carriers of pathogenic mutations in recessive PD genes, including device-aided treatments, will be further discussed. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Comprehensive Evaluation of Psychotic Features and Their Clinical Correlates in Early Parkinson’s Disease

Author

Pachi, Ioanna, primary, Papadopoulos, Vassilis, additional, Koros, Christos, additional, Simitsi, Athina Maria, additional, Bougea, Anastasia, additional, Bozi, Maria, additional, Papagiannakis, Nikos, additional, Soldatos, Rigas Filippos, additional, Kolovou, Dimitra, additional, Pantes, George, additional, Scarmeas, Nikolaos, additional, Paraskevas, Georgios, additional, Voumvourakis, Konstantinos, additional, Papageorgiou, Sokratis G., additional, Kollias, Konstantinos, additional, Stefanis, Nikos, additional, and Stefanis, Leonidas, additional

Published
2023
Full Text
View/download PDF

13. Double Trouble: Association of Malignant Melanoma with Sporadic and Genetic Forms of Parkinson’s Disease and Asymptomatic Carriers of Related Genes: A Brief Report

Author

Koros, Christos, primary, Simitsi, Athina-Maria, additional, Bougea, Anastasia, additional, Papagiannakis, Nikolaos, additional, Antonelou, Roubina, additional, Pachi, Ioanna, additional, Angelopoulou, Efthalia, additional, Prentakis, Andreas, additional, Zachou, Athena, additional, Chrysovitsanou, Chrysa, additional, Beratis, Ion, additional, Fragkiadaki, Stella, additional, Kontaxopoulou, Dionysia, additional, Eftymiopoulou, Efthymia, additional, Stanitsa, Evangelia, additional, Potagas, Constantin, additional, Papageorgiou, Sokratis G., additional, Karavasilis, Efstratios, additional, Velonakis, Georgios, additional, Prassopoulos, Vasilios, additional, Geronicola-Trapali, Xenia, additional, and Stefanis, Leonidas, additional

Published
2023
Full Text
View/download PDF

14. Serum Uric Acid as a Putative Biomarker in Prodromal Parkinson’s Disease: Longitudinal Data from the PPMI Study

Author

Koros, Christos, primary, Simitsi, Athina-Maria, additional, Papagiannakis, Nikolaos, additional, Bougea, Anastasia, additional, Prentakis, Andreas, additional, Papadimitriou, Dimitra, additional, Pachi, Ioanna, additional, Beratis, Ion, additional, Stanitsa, Evangelia, additional, Angelopoulou, Efthalia, additional, Antonelou, Roubina, additional, Bregianni, Marianna, additional, Lourentzos, Konstantinos, additional, Papageorgiou, Sokratis G., additional, Bonakis, Anastasios, additional, Trapali, Xenia Geronicola, additional, Stamelou, Maria, additional, and Stefanis, Leonidas, additional

Published
2023
Full Text
View/download PDF

15. Impact ofAPOEGenotype on Cognition in Idiopathic and Genetic Forms of Parkinson's Disease

Author

Koros, Christos, primary, Brockmann, Kathrin, additional, Simitsi, Athina‐Maria, additional, Bougea, Anastasia, additional, Liu, Hui, additional, Hauser, Ann‐Kathrin, additional, Schulte, Claudia, additional, Lerche, Stefanie, additional, Pachi, Ioanna, additional, Papagiannakis, Nikolaos, additional, Antonelou, Roubina, additional, Zahou, Athina, additional, Wurster, Isabel, additional, Efthymiopoulou, Efthymia, additional, Beratis, Ion, additional, Maniati, Matina, additional, Moraitou, Marina, additional, Michelakakis, Helen, additional, Paraskevas, Georgios, additional, Papageorgiou, Sokratis G., additional, Potagas, Constantin, additional, Papadimitriou, Dimitra, additional, Bozi, Maria, additional, Stamelou, Maria, additional, Gasser, Thomas, additional, and Stefanis, Leonidas, additional

Published
2023
Full Text
View/download PDF

17. Impact ofAPOEgenotype on cognition in idiopathic and genetic forms of Parkinson’s disease

Author

Koros, Christos, primary, Brockmann, Kathrin, additional, Simitsi, Athina-Maria, additional, Bougea, Anastasia, additional, Liu, Hui, additional, Hauser, Ann-Kathrin, additional, Schulte, Claudia, additional, Lerche, Stefanie, additional, Pachi, Ioanna, additional, Papagiannakis, Nikolaos, additional, Antonelou, Roubina, additional, Zahou, Athina, additional, Wurster, Isabel, additional, Efthymiopoulou, Efthymia, additional, Beratis, Ion, additional, Maniati, Matina, additional, Moraitou, Marina, additional, Michelakakis, Helen, additional, Paraskevas, Georgios, additional, Papageorgiou, Sokratis G., additional, Potagas, Constantin, additional, Papadimitriou, Dimitra, additional, Bozi, Maria, additional, Stamelou, Maria, additional, Gasser, Thomas, additional, and Stefanis, Leonidas, additional

Published
2022
Full Text
View/download PDF

18. Asymptomatic carriers of the p.A53T SNCA mutation: Data from the PPMI study

Author

Simitsi, Athina Maria, primary, Koros, Christos, additional, Stamelou, Maria, additional, Beratis, Ion, additional, Efthymiopoulou, Efthymia, additional, Papadimitriou, Dimitra, additional, Bougea, Anastasia, additional, Picillo, Marina, additional, Stanitsa, Evangelia, additional, Papagiannakis, Nikolaos, additional, Antonelou, Roubina, additional, Pachi, Ioanna, additional, Papageorgiou, Sokratis G., additional, Barone, Paolo, additional, and Stefanis, Leonidas, additional

Published
2022
Full Text
View/download PDF

19. Asymptomatic carriers of the p.A53T SNCA mutation: data from the PPMI study

Author

Simitsi, Athina Maria, primary, Koros, Christos, additional, Stamelou, Maria, additional, Beratis, Ion, additional, Efthymiopoulou, Efthymia, additional, Papadimitriou, Dimitra, additional, Bougea, Anastasia, additional, Picillo, Marina, additional, Stanitsa, Evangelia, additional, Papagiannakis, Nikolaos, additional, Antonelou, Roubina, additional, Pachi, Ioanna, additional, Papageorgiou, Sokratis G, additional, Barone, Paolo, additional, and Stefanis, Leonidas, additional

Published
2021
Full Text
View/download PDF

20. Serum uric acid and total bilirubin as putative biomarkers of resistance in Prodromal Parkinson’s disease: Longitudinal data from the PPMI study

Author

Koros, Christos, primary, Simitsi, Athina-Maria, additional, Bougea, Anastasia, additional, Papagiannakis, Nikolaos, additional, Prentakis, Andreas, additional, Papadimitriou, Dimitra, additional, Pachi, Ioanna, additional, Angelopoulou, Efthalia, additional, Beratis, Ion, additional, Efthymiopoulou, Efthymia, additional, Lourentzos, Konstantinos, additional, Bozi, Maria, additional, Papageorgiou, Sokratis G., additional, Trapali, Xenia Geronicola, additional, Bonakis, Anastasios, additional, Stamelou, Maria, additional, and Stefanis, Leonidas, additional

Published
2021
Full Text
View/download PDF

22. Impact of APOE Genotype on Cognition in Idiopathic and Genetic Forms of Parkinson's Disease.

Author

Koros, Christos, Brockmann, Kathrin, Simitsi, Athina‐Maria, Bougea, Anastasia, Liu, Hui, Hauser, Ann‐Kathrin, Schulte, Claudia, Lerche, Stefanie, Pachi, Ioanna, Papagiannakis, Nikolaos, Antonelou, Roubina, Zahou, Athina, Wurster, Isabel, Efthymiopoulou, Efthymia, Beratis, Ion, Maniati, Matina, Moraitou, Marina, Michelakakis, Helen, Paraskevas, Georgios, and Papageorgiou, Sokratis G.

Published
2023
Full Text
View/download PDF

23. Apathy: an underestimated feature in GBA and LRRK2 non-manifesting mutation carriers

Author

Pachi, Ioanna, primary, Koros, Christos, additional, Simitsi, Athina M, additional, Papadimitriou, Dimitra, additional, Bougea, Anastasia, additional, Prentakis, Andreas, additional, Papagiannakis, Nikolaos, additional, Bozi, Maria, additional, Antonelou, Roubina, additional, Angelopoulou, Efthalia, additional, Beratis, Ion, additional, Stamelou, Maria, additional, Trapali, Xenia Geronicola, additional, Papageorgiou, Sokratis G., additional, and Stefanis, Leonidas, additional

Published
2021
Full Text
View/download PDF

24. Serum Uric Acid in LRRK2 Related Parkinson’s Disease: Longitudinal Data from the PPMI Study

Author

Bougea, Anastasia, primary, Koros, Christos, additional, Papagiannakis, Nikolaos, additional, Simitsi, Athina-Maria, additional, Prentakis, Andreas, additional, Papadimitriou, Dimitra, additional, Pachi, Ioanna, additional, Antonelou, Roubina, additional, Angelopoulou, Efthalia, additional, Beratis, Ion, additional, Bozi, Maria, additional, Papageorgiou, Sokratis G., additional, Trapali, Xenia Geronicola, additional, Stamelou, Maria, additional, and Stefanis, Leonidas, additional

Published
2021
Full Text
View/download PDF

25. The factors associated with the presence of psychotic symptoms in the HELIAD Greek community study of older adults.

Author

Vasiliadis, Helen-Maria, Gournellis, Rossetos, Efstathiou, Vasiliki, Stefanis, Nikos, Kosmidis, Mary H., Yannakoulia, Mary, Dardiotis, Efthimios, Hadjigeorgiou, Georgios, Sakka, Paraskevi, Ntanasi, Eva, Pachi, Ioanna, Stefanis, Leonidas, and Scarmeas, Nikolaos

Subjects
HALLUCINATIONS, DELUSIONS, PSYCHOSES, RISK assessment, NEUROPSYCHOLOGICAL tests, SOCIOECONOMIC factors, INDEPENDENT living, QUESTIONNAIRES, DESCRIPTIVE statistics, HEARING disorders, DEMENTIA, LOGISTIC regression analysis, ODDS ratio, DISEASE complications, OLD age
Abstract

The prevalence and associated factors related to psychotic symptoms in older adults are understudied. The objectives were to assess the prevalence, incidence and factors associated with psychotic symptoms in a representative Greek sample of community living older adults. The sample includes n = 1,904 residents of the cities of Larissa and Maroussi in Greece participating in the Hellenic Longitudinal Investigation of Aging and Diet study with available data at baseline and n = 947 individuals at the 3-year follow-up. Past-month presence of delusions and hallucinations was assessed on the grounds of the 17 symptoms of the Columbia University Scale for Psychopathology in Alzheimer's Disease and 14 symptoms of the Neuropsychiatric Inventory Questionnaire. A comprehensive neuropsychological assessment for probable diagnosis of dementia and physical comorbidity was carried out by neurologists. Penalized logistic regression analyses were used to assess the socio-economic and clinical factors associated with psychotic symptoms. Past-month prevalence of psychotic symptoms was 1.9% and 1.0% when excluding cases of dementia. The prevalence of any delusion and hallucination was 0.8% and 0.3% when excluding dementia. The incidence of psychotic symptoms without dementia was 1.3%. Recent widows and farmers/breeders/craftsmen, versus public servants/teachers/executives, had both six times the odds of experiencing psychotic symptoms without dementia. Hearing impairment and the number of health conditions also increased the odds while increased age was protective. Psychotic symptoms unrelated to dementia constitute a considerable mental health problem in old age. Paranoid delusions were the most prevalent. Socio-economic and health status factors are significant predictors of psychotic symptoms. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

26. DaTSCAN (123I-FP-CIT SPECT) imaging in early versus mid and late onset Parkinson's disease: Longitudinal data from the PPMI study

Author

Koros, Christos Simitsi, Athina-Maria Prentakis, Andreas and Papagiannakis, Nikolaos Bougea, Anastasia Pachi, Ioanna and Papadimitriou, Dimitra Beratis, Ion Papageorgiou, Sokratis G. and Stamelou, Maria Trapali, Xenia Geronicola Stefanis, Leonidas

Abstract

Introduction: It has been reported that early onset Parkinson’s Disease (PD) patients have a less profound dopaminergic degeneration. The aim of the current study was to determine whether there are longitudinal differences in dopaminergic denervation [signal reduction in 123I-FP-CIT SPECT] in early versus mid and late onset PD. Methods: DaTSCAN (123I-FP-CIT SPECT) imaging was acquired at Parkinson’s Progression Markers Initiative (PPMI) imaging centers and sent to the imaging core for calculation of striatal binding ratios. Data from the PPMI database of 58 early de novo PD patients (age 50 years). Results: Although raw striatal binding ratios were higher in early onset versus mid/late onset PD, especially on the ipsilateral side, such differences were not observed, and were in fact reversed in the contralateral putamen, after age correction. The rate of signal decline was similar between the two groups. Interestingly, based on both raw and age-adjusted data, caudate nucleus and putamen asymmetry (contralateral/ipsilateral ratio) was more pronounced in early onset PD. Striatal asymmetry also significantly correlated with age at onset as a continuous variable. Conclusion: Early onset PD patients exhibited similar rates of decline of dopaminergic denervation compared to mid/late onset PD. These results are not supportive of a more benign disease in this subgroup. The more pronounced asymmetry in early onset PD may however signify a qualitatively different pattern of neurodegeneration compared to mid/late onset PD.

Published
2020

27. Serum Uric Acid Level as a Biomarker in Idiopathic and Genetic (p.A53T Alpha-Synuclein Carriers) Parkinson?s Disease: Data from the PPMI Study

Author

Koros, Christos Simitsi, Athina-Maria Papadimitriou, Dimitra and Bougea, Anastasia Prentakis, Andreas Papagiannakis, Nikolaos and Pachi, Ioanna Bozi, Marria Antonelou, Roubina Angelopoulou, Efthalia Beratis, Ion Papageorgiou, Sokratis G. Trapali, Xenia Geronicola Stamelouaef, Maria Stefanis, Leonidas

Abstract

Background: Blood uric acid level represents an emerging biomarker in Parkinson's disease (PD). Whether uric acid levels change in genetic forms of PD is just beginning to be explored. Objective: The aim of the present study was to assess differences in serum uric acid level among PD patients harboring the p.A53T mutation in the alpha-synuclein gene, idiopathic PD, and healthy controls. Methods: Longitudinal 5-year serum uric acid measurement data of 369 de novo idiopathic PD patients and 174 age- and gender-matched healthy controls have been downloaded from the Parkinson's Progression Markers Initiative (PPMI) database. Furthermore, we assessed baseline serum uric acid measurements of 24 p.A53T alpha-synuclein PD patients enrolled in PPMI and followed in our site as compared to 24 age-, gender- and disease duration-matched sporadic PD patients and 24 healthy controls. Results: Longitudinal serum uric acid measurements did not differ statistically between idiopathic PD patients and healthy controls (despite a trend for lower uric acid in the PD group) (p = 0.879). This was also true when male and female subgroups were assessed separately. The p.A53T SNCA mutation carrier PD group exhibited lower baseline serum uric acid level as compared to their matched healthy controls (p = 0.025). Conclusion: In the present study we did not replicate the established lower serum uric acid measurements in PD patients as compared to controls using PPMI data, possibly due to the fact that PD patients in baseline visit were de novo and the average disease duration was shorter than that observed in most epidemiological PD studies. The faster progression rate and increased disease severity in p.A53T PD possibly correlate with the lower serum uric acid observed in this subgroup.

Published
2020

28. The factors associated with the presence of psychotic symptoms in the HELIAD Greek community study of older adults

Author

Vasiliadis, Helen-Maria, primary, Gournellis, Rossetos, additional, Efstathiou, Vasiliki, additional, Stefanis, Nikos, additional, Kosmidis, Mary H., additional, Yannakoulia, Mary, additional, Dardiotis, Efthimios, additional, Hadjigeorgiou, Georgios, additional, Sakka, Paraskevi, additional, Ntanasi, Eva, additional, Pachi, Ioanna, additional, Stefanis, Leonidas, additional, and Scarmeas, Nikolaos, additional

Published
2021
Full Text
View/download PDF

30. REM sleep behavior disorder and other sleep abnormalities in p. A53T SNCA mutation carriers

Author

Simitsi, Athina Maria, primary, Koros, Christos, additional, Stamelou, Maria, additional, Papadimitriou, Dimitra, additional, Leonardos, Athanasios, additional, Bougea, Anastasia, additional, Papagiannakis, Nikolaos, additional, Pachi, Ioanna, additional, Angelopoulou, Efthalia, additional, Lourentzos, Konstantinos, additional, Bonakis, Anastasios, additional, and Stefanis, Leonidas, additional

Published
2020
Full Text
View/download PDF

31. 445 - The factors associated with the presence of psychotic symptoms in the HELIAD Greek community study of older adults

Author

Vasiliadis, Helen-Maria, primary, Gournelis, Rossettos, additional, Efstathiou, Vassia, additional, Stefanis, Nikos, additional, Kosmidis, Mary H., additional, Yannakoulia, Mary, additional, Dardiotis, Efthimios, additional, Hadjigeorgiou, Georgios, additional, Sakka, Paraskevi, additional, Ntanasi, Eva, additional, Pachi, Ioanna, additional, Stefanis, Leonidas, additional, and Scarmeas, Nikolaos, additional

Published
2020
Full Text
View/download PDF

34. Serum Uric Acid Level as a Biomarker in Idiopathic and Genetic (p.A53T Alpha-Synuclein Carriers) Parkinson’s Disease: Data from the PPMI Study

Author

Koros, Christos, primary, Simitsi, Athina-Maria, additional, Papadimitriou, Dimitra, additional, Bougea, Anastasia, additional, Prentakis, Andreas, additional, Papagiannakis, Nikolaos, additional, Pachi, Ioanna, additional, Bozi, Maria, additional, Antonelou, Roubina, additional, Angelopoulou, Efthalia, additional, Beratis, Ion, additional, Papageorgiou, Sokratis G., additional, Trapali, Xenia Geronicola, additional, Stamelou, Maria, additional, and Stefanis, Leonidas, additional

Published
2020
Full Text
View/download PDF

35. Circulating Brain‐Enriched MicroRNAs for Detection and Discrimination of Idiopathic and Genetic Parkinson's Disease

Author

Ravanidis, Stylianos, primary, Bougea, Anastasia, additional, Papagiannakis, Nikolaos, additional, Maniati, Matina, additional, Koros, Christos, additional, Simitsi, Athina‐Maria, additional, Bozi, Maria, additional, Pachi, Ioanna, additional, Stamelou, Maria, additional, Paraskevas, George P., additional, Kapaki, Elisabeth, additional, Moraitou, Marina, additional, Michelakakis, Helen, additional, Stefanis, Leonidas, additional, and Doxakis, Epaminondas, additional

Published
2019
Full Text
View/download PDF

37. Serum Uric Acid in LRRK2Related Parkinson’s Disease: Longitudinal Data from the PPMI Study

Author

Bougea, Anastasia, Koros, Christos, Papagiannakis, Nikolaos, Simitsi, Athina-Maria, Prentakis, Andreas, Papadimitriou, Dimitra, Pachi, Ioanna, Antonelou, Roubina, Angelopoulou, Efthalia, Beratis, Ion, Bozi, Maria, Papageorgiou, Sokratis G., Trapali, Xenia Geronicola, Stamelou, Maria, and Stefanis, Leonidas

Abstract

Previous studies have highlighted serum uric acid as a putative idiopathic Parkinson’s disease (iPD) biomarker. Only one study, so far, showed higher levels of serum uric acid in leucine-rich repeat kinase 2 (LRRK + 2) carriers compared to those who developed PD, however a longitudinal comparison between LRRK2 + PD and healthy controls (HC) has not been performed. The aim of this study was to determine whether there are longitudinal differences in serum uric acid between iPD, LRRK2 + PD and HC and their association with motor and non-motor features. Longitudinal data of uric acid of 282 de novo iPD, 144 LRRK2 + PD patients, and 195 age-matched HC were obtained from the Parkinson’s Progression Markers Initiative (PPMI) database. We also used longitudinal Montreal Cognitive Assessment (MoCA), Movement Disorder Society–Unified Parkinson’s Disease Rating Scale part III (MDS-UPDRS-III), Geriatric Depression Scale (GDS) scores, and DaTSCAN striatal binding ratios (SBRs). Longitudinal uric acid measurements were significantly lower in LRRK2 + PD patients compared to HC up to 5 years follow-up. There was no significant impact or correlation of adjusted or unadjusted uric acid levels with MoCA, MDS-UPDRS III, or GDS scores, the presence of RBD or DAT-SCAN SBRs. LRRK2 + PD group had significantly lower uric acid concentrations compared to HC after adjusting for age, sex and baseline BMI up to 5 years follow-up. There were no significant associations between uric acid levels and indices of disease severity. These findings identify serum uric acid as a marker linked to LRRK2 + PD.

Published
2021
Full Text
View/download PDF

38. Circulating Brain-enriched MicroRNAs for detection and discrimination of idiopathic and genetic Parkinson's disease.

Author

Ravanidis, Stylianos, Bougea, Anastasia, Papagiannakis, Nikolaos, Maniati, Matina, Koros, Christos, Simitsi, Athina‐Maria, Bozi, Maria, Pachi, Ioanna, Stamelou, Maria, Paraskevas, George P., Kapaki, Elisabeth, Moraitou, Marina, Michelakakis, Helen, Stefanis, Leonidas, Doxakis, Epaminondas, and Simitsi, Athina-Maria

Abstract

Background: A minimally invasive test for early detection and monitoring of Parkinson's disease (PD) is a highly unmet need for drug development and planning of patient care. Blood plasma represents an attractive source of biomarkers. MicroRNAs (miRNAs) are conserved noncoding RNA molecules that serve as posttranscriptional regulators of gene expression. As opposed to ubiquitously expressed miRNAs that control house-keeping processes, brain-enriched miRNAs regulate diverse aspects of neuron development and function. These include neuron-subtype specification, axonal growth, dendritic morphogenesis, and spine density. Backed by a large number of studies, we now know that the differential expression of neuron-enriched miRNAs leads to brain dysfunction.Objectives: The aim was to identify subsets of brain-enriched miRNAs with diagnostic potential for familial and idiopathic PD as well as specify the molecular pathways deregulated in PD.Methods: Initially, brain-enriched miRNAs were selected based on literature review and validation studies in human tissues. Subsequently, real-time reverse transcription polymerase chain reaction was performed in the plasma of 100 healthy controls and 99 idiopathic and 53 genetic (26 alpha-synucleinA53T and 27 glucocerebrosidase) patients. Statistical and bioinformatics analyses were carried out to pinpoint the diagnostic biomarkers and deregulated pathways, respectively.Results: An explicit molecular fingerprint for each of the 3 PD cohorts was generated. Although the idiopathic PD fingerprint was different from that of genetic PD, the molecular pathways deregulated converged between all PD subtypes.Conclusions: The study provides a group of brain-enriched miRNAs that may be used for the detection and differentiation of PD subtypes. It has also identified the molecular pathways deregulated in PD. © 2019 International Parkinson and Movement Disorder Society. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

39. Διερεύνηση των προσδιοριστικών παραγόντων της γονιμότητας των μεταναστών και γηγενών στην Ελλάδα

Author

Ντεμούσης, Μιχαήλ, Pachi, Ioanna, Νταούλη, Ιωάννα, and Βενέτης, Ιωάννης

Subjects
Fertility, Immigration, Μετανάστευση, 301.094 95, Γονιμότητα
Abstract

Στην παρούσα εργασία θα διερευνήσουμε τους προσδιοριστικούς παράγοντες της γονιμότητας των μεταναστριών στην Ελλάδα. Για του σκοπούς της ανάλυσης μας αντλούμε ατομικά στοιχεία από την Απογραφή-2001 για μετανάστριες ηλικίας 15-49 ετών που είναι εγκατεστημένες στην Ελλάδα. Αρχικά, εκτιμώνται εμπειρικά υποδείγματα γονιμότητας για το σύνολο των γυναικών ηλικίας 15-49 με σκοπό να προσδιοριστεί η σχετική θέση των μεταναστριών έναντι των γηγενών γυναικών. Στη συνέχεια εκτιμώνται αντίστοιχα υποδείγματα για μετανάστριες και γηγενείς, ξεχωριστά, λαμβάνοντας υπόψη μια ευρύτερη δέσμη ατομικών και άλλων μεταναστευτικών χαρακτηριστικών, όπως τα έτη διαμονής στην Ελλάδα. Επίσης εφαρμόζονται υποδείγματα γραμμικού διαχωρισμού των επιδράσεων ώστε να προσδιοριστεί η επίδραση των παρατηρούμενων και μη-παρατηρούμενων παραγόντων στη διαμόρφωση των διαφορών στα επίπεδα γονιμότητας μεταξύ μεταναστριών και γηγενών. Σύμφωνα με τα αποτελέσματα οι μετανάστριες εμφανίζονται να έχουν μεγαλύτερο αριθμό παιδιών σε σχέση με τις γηγενείς. Το εύρημα αυτό βρίσκεται σε συμφωνία με αντίστοιχα ευρήματα από τη σχετική διεθνή βιβλιογραφία. Όπως αναμενόταν η γονιμότητα των μεταναστριών συσχετίζεται άμεσα και με διάφορα μεταναστευτικά χαρακτηριστικά όπως τα έτη διαμονής, η χώρα προέλευσης και η γονιμότητα της χώρας προέλευσης. Τέλος να σημειωθεί ότι η διαφορά στη γονιμότητα μεταξύ μεταναστριών και γηγενών φαίνεται σε μεγάλο βαθμό να ερμηνεύεται από την διαφορετική κατανομή των παρατηρούμενων χαρακτηριστικών (ηλικία και γάμος) μεταξύ μεταναστριών και γηγενών.

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results